• About
  • Subscribe
  • Advertise
  • Contact
Friday, May 16, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Alcon launches breakthrough Vivity IOL in Australia

by Myles Hume
September 22, 2020
in Devices, Local, News, Products, Technology
Reading Time: 4 mins read
A A
Alcon Vivity and IOL data

Alcon's AcrySof IQ Vivity IOL was launched in Australia in September 2020.

Share on FacebookShare on Twitter

Alcon has officially ushered in what some Australian ophthalmologists are calling a new class in presbyopia-correcting intraocular lens (IOL) technology due to its ability to negate visual disturbances – the bane of many EDOF and multifocal IOL designs.

Australian surgeons got their first glimpse of the AcrySof IQ Vivity IOL at a virtual launch out of Sydney on 17 September hosted by media personality Tracey Spicer. They were presented with findings of clinical trials and heard from leading ophthalmologists and patients who have had early access to the lens.

Chandra Bala.

The launch of Vivity, an extended range of vision IOL that uses non-diffractive design called X-Wave technology, has been highly anticipated after some early adopters stated it could become their default lens for cataract surgery.

Last week’s virtual event featured presentations and a panel discussion with Associate Professor Chandra Bala, managing director at personalEYES, Associate Professor Michael Lawless from the Vision Eye Institute in Sydney, and Clinical Associate Professor Paul McCartney from Hobart Eye Surgeons.

Bala, who took part in a trial comparing Vivity with the Alcon Acrysof IQ monofocal, presented key findings from two US and global studies, which demonstrated how Vivity enables high-quality vision at far and intermediate ranges as well as functional up-close vision.

While patients may require spectacles for some near activities, a monofocal visual disturbance profile is said to be a key advantage for Vivity over other presbyopia-correcting designs. These include multifocals which may offer spectacle independence with some visual disturbances, or some EDOF designs that may require spectacles while also producing visual disturbances.

In his presentation, Bala showed that in bright light 94% of Vivity patients reported good or very good vision without spectacles for distance, which was comparable to Acrysof IQ patients (92%).

The AcrySof IQ Vivity has been launched in Australia. Image reproduced with permission of Alcon.

For intermediate, Vivity was superior with 92% reporting good vision compared with 63% for Acrysof IQ, and for up close those numbers were 57% for Vivity and 25% for Acrysof IQ. In dim light, Vivity also performed better over all distances.

“So you are not only getting good distance vision, but the patient actually feels the quality of vision for intermediate is as good, and I think that’s an important take home message because the next question is what about visual disturbance, the one thing that plagues most presbyopia-correcting IOLs?” Bala said.

‘Seamless quality’  

In another slide, Bala showed how Vivity offered a visual disturbance profile equivalent to a monofocal lens (Acrysof IQ).

Overall, 74% of Vivity and 72% of Acrysof IQ patients were ‘not bothered’ by starbursts; 83% of Vivity and 89% of Acrysof IQ weren’t bothered by haloes; and for glare those numbers were 78% for Vivity and 70% for Acrysof IQ.

Bala said Vivity had similar architecture to a monofocal, with a key difference being an added on component in the form of the X-Wave technology. It’s essentially a small shift in the lens in about one micron in thickness, affecting a 2.2mm-wide section in the centre of the lens.

“So for all practical intents and purposes, it’s overall designed as a monofocal lens but gives you an extended range of vision,” he said.

Michael Lawless.

Lawless, who has implanted 112 Vivity IOLs since December, said he was initially cautious. However, he was now convinced of the technology and labelled it “a new class of lens”.

“This is an evolution, if by evolution you mean that this does things that I can’t do with other lenses,” he said. “I have been stung by many lenses over the years, but I’m pleased to say this lens does exactly what it is meant to do.”

He said the mechanism of action is a process called trapezoidal phase shift. This alters the waveform by stretching and then shifting the wave of light so that it increases the depth of focus so the image is in focus over a wider area. It does this without losing light at any range which is why the quality of vision is better than other EDOF or multifocal lenses. These, he said, lose around 12-15% of the light energy at any given point.

Lawless said until Vivity, the Zeiss At Lara was his ‘go-to’ EDOF lens, but there was still gaps in vision between intermediate and distance.

“The thing about the Vivity is its seamless quality, there is no hunting for the right focal lengths. It just seems normal to patients; they have described it to me as the vision they felt like they had when they were 35,” he said.

“It’s effectively taken the monofocal part of the practice, but it’s wrong to call it my default lens. The way I think about it is that I have to think of a reason why I would not use the Vivity lens in this particular patient, and it’s actually pretty hard to find a patient these days in my practice who I wouldn’t put a Vivity in.”

More reading

An IOL to change the cataract surgery paradigm?

Tags: Acrysof IQAcrySof IQ Vivity IOLAlconAssociate Professor Chandra BalaAssociate Professor Michael LawlessClinical Associate Professor Paul McCartneyHobart Eye Surgeonsintraocular lensIOLmonofocalpersonalEYESSydneyVirtual launchVision Eye Institutevisual disturbanceVivityX-Wave technology

Related Posts

The cost of intravitreal eye injections to manage macular degeneration can discourage many older Australians from continuing treatment. Image: Rose Makin/stock.adobe.com.

Special Report: Intravitreal injections and bulk billing – good for business

by Rob Mitchell
May 16, 2025

Frequent intravitreal injections are vital to help many older Australians keep their eyesight, but the costs can be prohibitive. Insight...

A scene from the movie My Eyes, featuring optometrist Tsu Shan Chambers (right). Image: FanForce Films.

My Eyes film starring Australian optometrist set to open in theatres

by Staff Writer
May 16, 2025

A film highlighting the remarkable journey of a Australian mother determined to save her daughter’s eyesight, and starring a practising...

Dry eye disease affects more than 4 million Australians and one symptom can be chronic eye pain. Image: sruilk/Shutterstock.com.

Aussie link in research on device to combat chronic eye pain

by Staff Writer
May 16, 2025

Research involving Australian patients has returned positive results for a device intended for the treatment of chronic ocular surface pain...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited